University of Southern California


RFA-AI-20-079: Human Immunology Project Consortium (HIPC) (U19 Clinical Trial Optional)

Slots:                                        1

Internal Deadline:                      March 19, 2021

LOI:                                          May 4, 2021

External Deadline:                     June 4, 2021

Award Type:                              Cooperative Agreement

Estimated Number of Awards:    NIAID intends to commit $16M in FY 2022 to fund 5-8 awards.

Anticipated Amount:                     See above. The scope of the proposed project should determine the project period.  The maximum project period is 5 years.

Process for Limited Submissions: PIs must submit their application as a Limited Submission through the Office of Research Application Portal:

Materials to submit include:

(1) Single Page Proposal Summary (0.5” margins; single-spaced; font type: Arial, Helvetica, or Georgia typeface; font size: 11 pt). Page limit includes references and illustrations. Pages that exceed the 1-page limit will be excluded from review.

(2) CV – (5 pages maximum)

Note: The portal requires information about the PIs and Co-PIs in addition to department and contact information, including the 10-digit USC ID#, Gender, and Ethnicity. Please have this material prepared before beginning this application.


Who May Serve as PI:                    Note that the multiple PD(s)/PI(s) option may be used only for the Overall Program. Projects are limited to a single project lead per project and a single core lead per core within the multi-component application.

An individual can be PD/PI on only one application, including multiple PD/PI applications.

Purpose:                                   The purpose of this FOA is to characterize human immune responses/mechanisms elicited by vaccinations, vaccine adjuvants or natural infections by capitalizing on recent advances in immune profiling technologies. Studies supported under this FOA will measure the diversity and commonalities of human immune responses under a variety of conditions and longitudinally using high-throughput systems immunology approaches coupled with detailed clinical phenotyping in well-characterized human cohorts. The resulting data will be used to develop molecular signatures that define immune response profiles and identify biomarkers that correlate with the outcomes of vaccinations, vaccine adjuvants or natural infections in humans. An additional goal of this program is to promote rapid public access to HIPC-supported data and meta-data through public portals such as ImmPort.

Budgetary Requirements:           Application budgets are limited to $1,500,000 direct costs per year.

Visit our Institutionally Limited Submission webpage for more updates and other announcements.